Research output per year
Research output per year
Fingerprint
Dive into the research topics where Franz Zehentmayr is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Cone-Beam CT Segmentation for Intraoperative Electron Radiotherapy Based on U-Net Variants with Transformer and Extended LSTM Approaches
Vockner, S. (First author), Mattke, M. (Co-author), Messner, I. M. (Co-author), Gaisberger, C. (Co-author), Zehentmayr, F. (Co-author), Ellmauer, K. (Co-author), Ruznic, E. (Co-author), Karner, J. (Co-author), Fastner, G. (Co-author), Reitsamer, R. (Co-author), Roeder, F. (Co-author) & Stana, M. (Last author), 1 Feb 2025, In: Cancers. 17, 3, 14 p., 485.Research output: Contribution to journal › Original Article › peer-review
Open Access1 Citation (Web of Science) -
Delta Changes in [18F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation–Chemoimmunotherapy
Grambozov, B. (First author), Zamani-Siahkali, N., Stana, M. (Co-author), Beheshti, M. (Co-author), Ruznic, E. (Co-author), Iskakova, Z. (Co-author), Karner, J. (Co-author), Zellinger, B. (Co-author), Gerum, S. (Co-author), Roeder, F. (Co-author), Pirich, C. (Co-author) & Zehentmayr, F. (Last author), 31 Jul 2025, In: BIOMEDICINES. 13, 8, 15 p., 1866.Research output: Contribution to journal › Original Article › peer-review
Open Access -
Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
Zehentmayr, F. (First author), Ruznic, E. (Co-author), Feurstein, P. (Co-author), Langer, B. (Co-author), Grambozov, B. (Co-author), Klebermass, M. (Co-author), Hochreiter, A. (Co-author), Purevdorj, A. (Co-author), Gruber, G. (Co-author), Minasch, D. (Co-author), Böhmer-Breitfelder, B. (Co-author), Steffal, C. (Co-author), Kirchhammer, K. (Co-author), Stranzl, H. (Co-author), Röder, F. (Co-author), Dieckmann, K. (Last author) & ALLSTAR Group, 25 Apr 2025, In: Cancers.Research output: Contribution to journal › Original Article › peer-review
Open Access1 Citation (Web of Science) -
Immediate start of durvalumab after chemoradiotherapy in unresectable non-small cell lung cancer UICC stage III: early results from the TORG1937/DATE study
Grambozov, B. (First author), Stana, M. (Co-author) & Zehentmayr, F. (Last author), Jan 2025, In: Journal of Thoracic Disease. 17, 1, p. 1-4 4 p.Research output: Contribution to journal › Letter to the editor › peer-review
Open Access1 Citation (Web of Science) -
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
Ruznic, E. (First author), Klebermass, M. (Co-author), Zellinger, B. (Co-author), Langer, B. (Co-author), Grambozov, B. (Co-author), Purevdorj, A. (Co-author), Karner, J. (Co-author), Gruber, G. (Co-author), Stana, M. (Co-author), Minasch, D. (Co-author), Kirchhammer, K., Steffal, C. (Co-author), Stranzl, H. (Co-author), Moosbrugger, R. (Co-author), Feurstein, P. (Co-author), Dieckmann, K. (Co-author), Zehentmayr, F. (Last author) & ALLSTAR Group, 1 Feb 2025, In: Journal of Clinical Medicine. 14, 3, 16 p., 945.Research output: Contribution to journal › Original Article › peer-review
Open Access2 Citations (Web of Science)
Projects
- 2 Finished
-
NR2F1-ERalpha induced hsa-miR-375 promotes local relapse in breast cancer by targeting RASD1
Sedlmayer, F. (Further contributor), Zehentmayr, F. (PI), Zellinger, B. (Further contributor) & Kronberger, C. (Further contributor)
1/02/18 → 1/02/19
Project: Research
-
Functional pathways in early stage breast cancer regulated by hsa-miR-375 and hsa-miR-3651
Zehentmayr, F. (Further contributor)
15/12/15 → 15/12/16
Project: Research